Stocks
Invest in Stocks
Invest in stocks, ETFs, IPOs with fast orders. Track returns on your stock holdings and view real-time P&L on your positions.
F&O
Amanta Healthcare IPO
Amanta Healthcare Ltd
₹14,280 /119 sharesMinimum Investment
Amanta Healthcare IPO Listing Details
| Listed On | Issue Price | Listing Price | Listing Gains |
|---|---|---|---|
| BSE | ₹126.00 | ₹135.00 | ₹9.00 (7.14%) |
Amanta Healthcare IPO Details
| Bidding Dates | Min. Investment | Lot Size | Price Range |
|---|---|---|---|
| 1 Sep ‘25 - 3 Sep ‘25 | ₹14,280 | 119 | ₹120 - ₹126 |
| Issue Size | IPO Doc |
|---|---|
| 126.00Cr | RHP PDF |
Subscription rate
As of 03 Sep'25, 04:01 PM
| Qualified Institutional Buyers | 16.81x |
| Non-Institutional Investor | 185.14x |
| Retail Individual Investor | 48.73x |
| Total | 68.84x |
About Amanta Healthcare
Founded in
1994
Managing director
Mr. Bhavesh Patel
Parent organisation
Amanta Healthcare Ltd
Amanta Healthcare Ltd IPO
https://www.youtube.com/watch?v=mfVOgoOHcL0
Strengths & Financials of Amanta Healthcare
Strengths
Risks
Amanta Healthcare claims to operate four production lines for LVPs, which include two lines for conventional single-port containers using ABFS technology and two lines for SteriPort products based on ISBM technology. The company also claims to operate three SVP manufacturing lines, two with ABFS systems and one conventional line for filling three-piece containers.
The company claims that its products are registered in 19 countries and comply with a wide range of international regulatory standards. In FY25, it exported branded products to 21 countries. The company also states that it engages in product partnerships by manufacturing for other pharmaceutical companies.
Amanta Healthcare claims to offer a wide variety of closure systems, including nipple heads, twist-off, and screw types, as well as container fill volumes. The company further states that it has a portfolio of 47 registered products across 120 international jurisdictions, providing a diverse product base that supports consistent and sustainable business growth.
Sterile liquid manufacturing is a specialised process, and the company claims that it can provide fill volumes ranging from 2 ml to 1,000 ml at a single facility with multiple closure system options. The company also states that it has adopted a roll-on/roll-off (RO/RO) configuration for its water system to ensure efficiency and compliance with quality standards.
The company is ISO 9001:2015 certified for its quality management systems, ISO 13485:2016 certified for its quality management systems of medical devices, ISO 14001:2015 certified for its environmental management systems, and ISO 45001:2018 certified for its occupational health and safety management systems. It is also World Health Organisation Good Manufacturing Practices (WHO-GMP) certified.
The company claims to have a network of over 320 distributors and stockists. It mainly distributes products to Indian distributors, who then supply these to hospitals, nursing homes, and similar institutions.
The company holds a certification from Det Norske Veritas (DNV) for exporting medical device products. Its cGMP-compliant facilities enable it to produce sterile liquid formulations across multiple categories, including quinolones, antibiotics, antifungals, diuretics, anti-anaerobics, ophthalmic, and respiratory products.
The company’s entire manufacturing facility is located in Hariyala, Kheda district, Gujarat. Since all products are produced at this single site, any disruption at the unit or in the state could adversely affect production and impact the company’s business operations and finances.
The company has very high finance costs. Finance costs accounted for Rs 27.95 crore (45.78 percent) of the company’s earnings before interest, tax, depreciation, and amortisation (EBITDA) in FY25, Rs 33.64 crore (57.25 percent) in FY24, and Rs 35.27 crore (62.64 percent) in FY23. Such high borrowing costs make it expensive to raise funds for new projects or expansion. Any failure to reduce these finance costs could adversely affect the company’s growth, profitability, and cash flows.
The company’s top 5 suppliers accounted for Rs 58.97 crore (61.91 percent) of the company’s total material sourced in FY25, Rs 51.36 crore (54.95 percent) in FY24, and Rs 52.55 crore (53.07 percent) in FY23. Any disruption in supplies from one or more of these suppliers could adversely affect the company’s business and finances.
The company’s raw materials and packaging materials include LDPE and PP granules, among others. The top 10 raw materials accounted for Rs 81.95 crore (86.02 percent) of the company’s total raw material sourced in FY25, Rs 82.01 crore (87.75 percent) in FY24, and Rs 84.27 crore (85.12 percent) in FY23. As the prices of polymers are closely linked to crude oil, any volatility in global crude prices or changes in the demand and supply of polymers could directly impact the company’s procurement costs, adversely affecting its operations and finances.
A significant portion of the plastic granules that are used in production is sourced from international suppliers. Plastic granules accounted for Rs 33.34 crore (32.92 percent) of the company’s total material consumed in FY25, Rs 27.47 crore (32.08 percent) in FY24, and Rs 31.52 crore (31.31 percent) in FY23. Any sudden exposure to risks associated with import duties or regulatory restrictions can negatively impact the procurement process of plastic granules and adversely affect the company’s business operations.
The company derives a significant portion of its business from exports. Exports accounted for Rs 90.83 crore (33.06 percent) of the company’s total revenue in FY25, Rs 82.17 crore (29.31 percent) in FY24, and Rs 80.18 crore (30.94 percent) in FY23. This exposes the company to risks such as regulatory compliance in foreign markets, exchange rate fluctuations, and rising tariffs, any of which could negatively impact its profitability, financial condition, and operations.
The company’s top 10 clients accounted for Rs 78.54 crore (28.59 percent) of the company’s total revenue in FY25, Rs 79.42 crore (28.33 percent) in FY24, and Rs 81.39 crore (31.41 percent) in FY23. If the company loses any of these customers or business from any of them decreases, it would adversely affect the company’s finances and operations.
In FY23, the company reported a net loss of Rs 2.11 crore, primarily due to a write-off of deferred tax liability of Rs 7.89 crore, which significantly increased the overall tax burden and resulted in a negative PAT. The company further states that, since its profitability is mainly influenced by raw material costs and finance costs, there is no assurance that similar situations will not arise in the future.
The company has experienced high employee attrition, with rates of 33.82 percent in FY23, 25.90 percent in FY24, and 9.88 percent in FY25. Although attrition declined significantly in FY25, the levels in FY23 and FY24 were still high compared to industry standards. There is no assurance that the company will not face workforce-related challenges or disputes in the future, which could disrupt operations and affect business continuity.
As of FY25, the company had contingent liabilities amounting to Rs 11.59 crore. If any of these contingent liabilities materialise, it could adversely affect the company’s financial condition.
The company is involved in certain legal and regulatory proceedings, including some tax-related cases. Any adverse judgments in any of these cases can be detrimental to the company’s business prospects.
As of FY25, the company had outstanding financial indebtedness of Rs 194.51 crore. Any failure to service or repay these loans can harm the company’s operations and financial position.
Amanta Healthcare Financials
*All values are in Rs. Cr
No Graph Data To Display
Application Details of Amanta Healthcare IPO
| Apply as | Price band | Apply upto |
|---|---|---|
| Regular | ₹120 - 126 | ₹2 Lakh |
| High Networth Individual | ₹120 - 126 | ₹2 - 5 Lakh |
For Amanta Healthcare IPO, eligible investors can apply as Regular.